Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder-March 2024-www.financetom.com

Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder

Dec 16, 2024 6:03 AM

08:35 AM EST, 12/16/2024 (MT Newswires) -- Mind Medicine (MNMD) said Monday that a first patient has been dosed in its phase 3 Voyage study that is evaluating MM120 ODT for the treatment of generalized anxiety disorder.

The company said the trial is the first of two phase 3 studies evaluating the efficacy and safety of MM120 ODT versus placebo. Mind Medicine said the second study, called Panorama, will be conducted in the US and Europe and is expected to be initiated in H1 2025.

Previous page： Miller Environmental Group completes acquisition of ACE Environmental Services Next page： Galecto Announces Acquisition of Damora Therapeutics

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Miller Environmental Group completes acquisition of ACE Environmental Services

Nov 10, 2025

CALVERTON, N.Y., Nov. 10, 2025 /PRNewswire/ -- Miller Environmental Group, a Coalesce Capital portfolio company, today announced that it has acquired ACE Environmental Services, a full-service provider of environmental services for commercial, industrial, marine, and residential markets, operating throughout the Mid-Atlantic region. The acquisition of ACE marks another important step in Miller's strategic expansion and underscores the company's broader growth...

Galecto Announces Acquisition of Damora Therapeutics

Nov 10, 2025

Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a potentially best-in-class monoclonal antibody targeting mutCALR Combined...

Tsavorite secures more than $100 million in pre-orders for AI chips to scale workflows

Nov 10, 2025

Nov 10 (Reuters) - AI startup Tsavorite Scalable Intelligence said on Monday it has secured more than $100 million in pre-orders from enterprises and cloud providers across United States, Asia and Europe to deploy its chips, which are used to scale AI workloads. The company has seen strong demand for its Omni Processing Unit, a compute architecture which unifies central...

TEGNA Inc. Reports Third Quarter 2025 Results

Nov 10, 2025

As previously announced on August 19, 2025, TEGNA Inc. ( TGNA ) and Nexstar Media Group entered into a definitive agreement, under which Nexstar will acquire all outstanding shares of TEGNA ( TGNA ) for $22.00 per share in a cash transaction valued at $6.2 billion Proposed transaction is expected to close by the second half of 2026, subject to...